Company announcement - No. 42 / 2016
Copenhagen, 31 October 2016 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations , Zealand issues announcements to state the total number of shares and voting rights in the company at the end of a calendar month in which there have been changes to its share capital.
In company announcement no. 40/2016 on 4 October 2016 Zealand announced increases in its share capital after completion of an offering ("the Offering") of new Zealand shares subscribed for at a market price of DKK 96.90 by biotech specialist investors and other institutional investors in the U.S. and Europe. Following from this announcement, the table below lists the total number of shares and voting rights in Zealand as of 31 October 2016.
Number of shares
(nominal value of DKK 1 each)
(nominal value in DKK)
|Number of voting rights|
|31 October 2016||26,062,253||26,062,253||26,062,253|
For further information, please contact:
Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, email: email@example.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.
The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia ® outside the United States and approved as Adlyxin TM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus ® (insulin glargine) which product is under regulatory review in the United States and in Europe.
Zealand's proprietary pipeline includes: Dasiglucagon * (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide* (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN)